Neuroscience and Mental Health Group Journals’ Post

🎥 New Special Report! 🎥 We’re excited to present a special 5-part series on Embracing New Therapies in Schizophrenia Management, with insights from leading subject matter experts Rishi Kakar, MD, of Segal Trials, Andrew Cutler, MD, Neuroscience Education Institute, and moderator Sam Clark, MD PhD, of Terran Biosciences. In this series, we dive deep into the groundbreaking FDA-approved schizophrenia treatment, xanomeline and trospium chloride capsules (Cobenfiy; Bristol Myers Squibb), and its novel mechanism of action targeting muscarinic receptors instead of traditional dopamine pathways. The series highlights key clinical trial data, symptom management, and how these new therapies could revolutionize treatment for patients who haven't fully responded to traditional antipsychotics. Watch and learn how these advancements may shape the future of schizophrenia care, improve patient outcomes, and address unmet needs in managing this complex condition. In the segment below, the experts discuss the application of clinical trial data to real-world settings. Use the link for the full series! https://lnkd.in/eDvyx_9S #Schizophrenia #Neuropsychiatry #MentalHealth #Psychiatry

Long noncoding RNAs emerge as promising biomarkers for mood disorders. New review highlights potential of blood-based RNA molecules for diagnosis and treatment of depression and bipolar disorder. In a groundbreaking peer-reviewed review article, researchers have uncovered compelling evidence that long noncoding RNAs - molecules once dismissed as "junk DNA" - may hold the key to revolutionizing how we diagnose and treat mood disorders. The study, published in the journal Genomic Psychiatry (Genomic Press, New York), reveals that these RNA molecules circulating in blood samples could serve as powerful biomarkers for conditions like major depression and bipolar disorder, potentially leading to more accurate diagnoses and personalized treatments. For more information, click here for the full, open-access PDF: https://lnkd.in/dCnX5gaT The EurekAlert! news release can be found here: https://lnkd.in/dGV_5efy #UAB #YogeshDwivedi #MentalHealth #MentalHealthMatters #LncRNABiomarkers #MoodDisorderResearch #DepressionBiology #BipolarBiomarkers #PsychiatricGenomics #EpigeneticsAndMentalHealth #CirculatingLncRNA #PersonalizedPsychiatry #BrainEpigenetics #MolecularPsychiatry #PrecisionMentalHealth #BiomarkerDiscovery #DepressionDiagnosis #BipolarTreatment #NoncodingRNA #PsychiatricBiomarkers #MentalHealthGenomics #RNABiomarkers #BloodBasedBiomarkers #FutureOfPsychiatry

*SPRAVATO AS MONOTHERAPY FOR TRD!* Patients on Spravato for treatment resistant depression may soon no longer need to take an oral antidepressant…. My clinical experience all these years has been validated by this research poster presented Psych Congress 2 weeks ago Here are highlights from the poster: Esketamine Nasal Spray for Treatment-Resistant Depression -Study Context: A randomized, double-blind study presented at Psych Congress 2024 examined esketamine nasal spray monotherapy in adults with treatment-resistant depression. -Participant Criteria: Adults with major depressive disorder (MDD) with no psychotic features, high depressive symptom scores, and nonresponse to ≥2 oral antidepressants (OADs) were included. -Study Design: After a 2-week OAD-free period, participants (n=378) were randomized (2:1:1) to placebo or ESK doses (56mg/84mg) twice weekly for 4 weeks. -Key Findings: -Primary Endpoint: Mean change in MADRS score at day 28 was significantly better for ESK vs. placebo (56mg: −5.1, 84mg: −6.8; P< 0.001). -Secondary Endpoint: At day 2, MADRS score changes for ESK (56mg: p=0.004; 84mg: P=0.006) also outperformed placebo. -Safety Profile: Common adverse events (≥10%) included nausea, dissociation, dizziness, and headache. No new safety concerns emerged. The full manuscript has been submitted to JAMA, Journal of the American Medical Association Psychiatry and if accepted and published, will be out in 2025. Check out this article to learn more: https://lnkd.in/eEq3w5x9 • #PsychCongress2024 • #Esketamine • #TreatmentResistantDepression • #MentalHealthResearch • #Psychiatry • #ClinicalStudy • #DepressionTreatment • #EsketamineEfficacy • #MentalHealthAwareness • #InnovativeTherapies • #DepressionResearch • #Psychopharmacology

Researchers at Dalhousie University, led by Nelofar Kureshi, have explored the connection between traumatic brain injury (TBI) and the development of new-onset psychiatric disorders (NPDs). Using a dataset of 3,453 TBI patients and 13,112 controls from a provincial trauma registry, they applied latent class analysis to uncover distinct phenotypes within the TBI population. The results showed that TBI patients are significantly more likely to develop NPDs compared to non-TBI individuals, with odds ratios of 2.78 for those without pre-injury psychiatric history and 2.36 for those with prior psychiatric conditions. Eight different phenotypes were identified, each showing varying risks for NPD development, influenced by factors like age, injury severity, length of hospital stay, and discharge destination. For example, older adults requiring extended recovery and supportive care showed a 53% higher risk of developing NPDs compared to younger individuals with shorter recovery times. This research emphasizes the need for tailored psychiatric care, particularly early intervention based on individual risk profiles. By identifying specific patient clusters, this study offers a framework for improving mental health outcomes in TBI patients through targeted, phenotype-driven care strategies. The findings highlight the importance of integrating psychiatric risk assessments into TBI patient care, particularly at discharge, to better manage long-term psychiatric effects and improve patient recovery. #TBI #Psychiatry #Neuroscience #MentalHealth #HealthcareInnovation #PublicHealth #TraumaCare

https://lnkd.in/gWu7Zzwg                                                             Article title: Perrotta Integrative Clinical Interviews (PICI-2): Innovations to the first model, the study on the new modality of personological investigation, trait diagnosis and state diagnosis, and the analysis of functional and dysfunctional personality traits. An integrated study of the dynamic, behavioural, cognitive and constructivist models in psychopathological diagnosis. Research   Author(s): Giulio Perrotta Journal: Annals of Psychiatry and Treatment   Journal ISSN: 2640-8031 Abstract: Purpose: As a result of clinical findings it is necessary to make some changes to the previous model, the first version. The second version of the PICI model (Perrotta Integrative Clinical Interviews) improves the previous version by introducing some interpretative corrections, especially with regard to dysfunctional hyperactivation, unitary diagnosis, symptomatological persistence, categorical absorption, trait diagnosis and state diagnosis, egosyntony and egodystonia, reducing the items from 150 to 128 for the PICI-2C questionnaire and from 195 to 173 for the PICI-2TA questionnaire. The second version of the PICI is also enriched by a third questionnaire, PICI-2FT, always administered by the therapist after the clinical interview, with 18 items, capable of investigating functional personality traits and thus completing in a more descriptive way the personality picture of the patient in its functional and structural totality. #PersonalityDisorders #PICI1 #PICI2 #MMPIIII #BiologicalPsychiatry #Psychopharmacotherapy #PsychologicalMedicine #ForensicPsychiatry #SocialPsychiatry #Sociotherapy #PTSD #Peertechz #PeertechzPublications #ChildAndAdolescentPsychiatry #AddictionPsychiatry #MoodDisorders #Nosography #Schizophrenia

🌍 A recent study in The Lancet Psychiatry revealed that 1 in 2 people worldwide will develop a mental health disorder during their lifetime. 🧠 With up to 46% of depression patients not fully responding to traditional antidepressants (National Institutes of Health), the need for new treatments is more critical than ever. This #WorldMentalHealthDay, Cumulus Neuroscience is proud to work with Delix Therapeutics, a company transforming brain health by developing treatments that are safe, fast-acting, and long-lasting. By targeting #neuroplasticity and bringing the first novel #neuroplastogen to the clinic, Delix is bringing much-needed hope to those facing difficult-to-treat #neuropsychiatric and neurological disorders. #WMHD2024 #CNS #DigitalBiomarkers #Innovation #MentalHealthMatters

🌍 A recent study in The Lancet Psychiatry revealed that 1 in 2 people worldwide will develop a mental health disorder during their lifetime. 🧠 With up to 46% of depression patients not fully responding to traditional antidepressants (National Institutes of Health), the need for new treatments is more critical than ever. This #WorldMentalHealthDay, Cumulus Neuroscience is proud to work with Delix Therapeutics, a company transforming brain health by developing treatments that are safe, fast-acting, and long-lasting. By targeting #neuroplasticity and bringing the first novel #neuroplastogen to the clinic, Delix is bringing much-needed hope to those facing difficult-to-treat #neuropsychiatric and neurological disorders. #WMHD2024 #CNS #DigitalBiomarkers #Innovation #MentalHealthMatters

🌍 A recent study in The Lancet Psychiatry revealed that 1 in 2 people worldwide will develop a mental health disorder during their lifetime. 🧠 With up to 46% of depression patients not fully responding to traditional antidepressants (National Institutes of Health), the need for new treatments is more critical than ever. This #WorldMentalHealthDay, Cumulus Neuroscience is proud to work with Delix Therapeutics, a company transforming brain health by developing treatments that are safe, fast-acting, and long-lasting. By targeting #neuroplasticity and bringing the first novel #neuroplastogen to the clinic, Delix is bringing much-needed hope to those facing difficult-to-treat #neuropsychiatric and neurological disorders. #WMHD2024 #CNS #DigitalBiomarkers #Innovation #MentalHealthMatters

🌍 A recent study in The Lancet Psychiatry revealed that 1 in 2 people worldwide will develop a mental health disorder during their lifetime. 🧠 With up to 46% of depression patients not fully responding to traditional antidepressants (National Institutes of Health), the need for new treatments is more critical than ever. This #WorldMentalHealthDay, Cumulus Neuroscience is proud to work with Delix Therapeutics, a company transforming brain health by developing treatments that are safe, fast-acting, and long-lasting. By targeting #neuroplasticity and bringing the first novel #neuroplastogen to the clinic, Delix is bringing much-needed hope to those facing difficult-to-treat #neuropsychiatric and neurological disorders. #WMHD2024 #CNS #DigitalBiomarkers #Innovation #MentalHealthMatters

🌍 A recent study in The Lancet Psychiatry revealed that 1 in 2 people worldwide will develop a mental health disorder during their lifetime. 🧠 With up to 46% of depression patients not fully responding to traditional antidepressants (National Institutes of Health), the need for new treatments is more critical than ever. This #WorldMentalHealthDay, Cumulus Neuroscience is proud to work with Delix Therapeutics, a company transforming brain health by developing treatments that are safe, fast-acting, and long-lasting. By targeting #neuroplasticity and bringing the first novel #neuroplastogen to the clinic, Delix is bringing much-needed hope to those facing difficult-to-treat #neuropsychiatric and neurological disorders. #WMHD2024 #CNS #DigitalBiomarkers #Innovation #MentalHealthMatters